Is TAVR at Hospitals Without Backup Cardiovascular Surgery Feasible?

Patients undergoing transcatheter aortic valve replacement (TAVR) at hospitals without cardiovascular surgery available are at significantly higher risk. That in itself is a call for attention; however, a propensity-matched analysis shows that the short- and long-term mortality rates are similar among patients treated at hospitals with and without cardiovascular surgery backup.

Debemos tener en cuenta a la isquemia crítica de MM II en el TAVIThis debate emerged a few years ago in relation to coronary angioplasty, until the question was finally answered at the American Heart Association (AHA) 2016 Congress, reaching the conclusion that both alternatives were equally safe. However, there is a difference between treating coronary arteries nd treating a valve, where potential complications may reach an entirely different level.

 

This study included high-risk or inoperable patients with severe aortic stenosis who underwent the procedure at institutions with and without cardiovascular surgery available in case of complications. Current guidelines recommend that this procedure be conducted only at hospitals where surgery is available.


Read also: Aortic Stenosis and Dialysis: Is TAVR the Strategy of Choice?


Researchers evaluated 1822 consecutive patients from the Austrian TAVR registry; 290 (15.9%) underwent the procedure at a site with no available surgery, whereas the remaining 1532 patients (84.1%) were treated at sites with surgery permanently available.

 

Patients treated at sites with no surgical availability had a higher peri-operative risk, as defined by the EuroSCORE (20.9% vs. 14.2%; p < 0.001), compared with patients treated in higher-complexity hospitals.


Read also: AHA 2018 | Use of Balloon Counterpulsation According to IABP-SHOCK II Trial.


In an analysis of raw figures, peri-procedural survival in hospitals without surgery was 96.9% vs. 98.6% (p = 0.034), whereas 30-day survival was 93.1% vs. 96.0% (p = 0.039), and 1-year survival was 80.9% vs 86.1% (p = 0.017), respectively. The difference in risk among populations was an obvious confounding variable, among others, which warranted propensity score matching; after its use, all significant differences disappeared in all time points.

 

Conclusion

According to this study, patients undergoing transfemoral TAVR in hospitals without cardiovascular surgery have similar short- and long-term mortality rates compared with patients who undergo the same procedure in higher-complexity sites with a surgical team available in case of any complication. This is a consequence of the mass use of TAVR; however, many more studies are required for guidelines to be changed.

 

Original title: Impact of On-Site Cardiac Surgery on Clinical Outcomes After Transfemoral Transcatheter Aortic Valve Replacement.

Reference: Florian Egger et al. J Am Coll Cardiol Intv 2018;11:2160-7.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TEER plus optimal medical therapy versus medical therapy alone in functional mitral regurgitation

Mitral regurgitation (MR) is a highly prevalent valvular heart disease that, in advanced stages and when left untreated, is associated with reduced quality of...

VECTOR: First Percutaneous Aorto-Coronary Bypass Case, a New Conceptual Approach

Coronary obstruction represents one of the most severe complications associated with transcatheter aortic valve implantation, particularly in valve-in-valve scenarios involving surgical bioprostheses, narrow aortic...

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...

TEER plus optimal medical therapy versus medical therapy alone in functional mitral regurgitation

Mitral regurgitation (MR) is a highly prevalent valvular heart disease that, in advanced stages and when left untreated, is associated with reduced quality of...

Hybrid Coronary Revascularization versus Conventional Bypass Surgery in Left Main Coronary Artery Disease

Significant left main coronary artery (LMCA) disease continues to represent a therapeutic challenge, particularly in patients with complex multivessel disease and high SYNTAX scores,...